# OnCo record panoptimox-prodige-35 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/panoptimox-prodige-35/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "panoptimox-prodige-35", "NCT02352337" ;
  schema:name "PANOPTIMOX-PRODIGE 35"@en ;
  schema:alternateName "PRODIGE 35"@en, "PANOPTIMOX"@en ;
  schema:description "PANOPTIMOX showed that people whose pancreatic cancer is controlled after four months of FOLFIRINOX can drop to a gentler fluorouracil maintenance without losing survival, living longer before their quality of life fell; the alternating gemcitabine strategy did worse."@en ;
  schema:url <https://onco.cc/trials/panoptimox-prodige-35/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02352337>, <https://doi.org/10.1200/JCO.20.03329> ;
  onco:status "completed" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/leucovorin/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:terms <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/peripheral-neuropathy/> .